



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

November 14, 2023

Corporate Relationship Department
M/s. BSE Ltd.
Dalal Street, Fort
Mumbai 400 001

Manager – Listing
M/s. National Stock Exchange of India Ltd
“Exchange Plaza”, Bandra – Kurla Complex
Bandra (E) **Mumbai 400 051**

Scrip Code: **524816**

Scrip Code: **NATCOPHARM**

Dear Sir/Madam,

Please find enclosed herewith the disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for your information.

Thanking you,

Yours faithfully
For NATCO Pharma Limited

Ch. Venkat Ramesh
Company Secretary &
Compliance Officer



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

Ref: PR/07/2023-24

Press Release

Hyderabad, 14th November, 2023

NATCO records ₹1060.8 Crore consolidated revenue and ₹369 Crore of profit after tax, for the Second Quarter, FY2024

Hyderabad based NATCO Pharma Limited (NSE: NATCOPHARM; BSE: 524816) recorded consolidated total revenue of ₹1060.8 Crore for the Second quarter of FY2024 that ended on 30th September 2023, as against ₹452.6 Crore for the same period last year, reflecting a growth of 134%. The net profit for the period, on a consolidated basis, was ₹369 Crores as against ₹56.8 Crore same period last year, showing significant growth.

The company business was strong during the quarter due to growth in formulation exports and increased sales in domestic agrochemical business.

Segmental Revenue Split (All Figures in ₹ Crore)-

Segment	Revenue, Q2 FY24	Revenue, Q1 FY24	Revenue, Q2 FY23
API	77.8	75.1	44.1
Formulations, Domestic	102.5	132.4	93.5
Formulations, Exports (incl. Profit Share & Foreign Subs)	792.3	884.2	283.4
Other Operating income & non-operating income	32.4	23.8	28.6
Crop Health Sciences (CHS)	55.8	44.7	3.0
TOTAL	1060.8	1160.2	452.6

The Board of Directors had declared second interim dividend of ₹ 1.25 per equity share of ₹2.0 each, for FY 2024.

For NATCO Pharma Limited

Ch Venkat Ramesh
Company Secretary &
Compliance Officer